Sanofi Pasteur signs infectious disease deal with Vivalis
This article was originally published in Scrip
Executive Summary
Sanofi Pasteur, the vaccines division of Sanofi-Aventis, is to pay the French biopharmaceutical company Vivalis €3 million up front as part of a deal to discover and develop fully human monoclonal antibodies against infectious diseases.